Jingying Zhang, Qi Zhang, Yu Lou, Qihan Fu, Qi Chen, Tao Wei, Jiaqi Yang, Jinlong Tang, Jianxin Wang, Yiwen Chen, Xiaoyu Zhang, Jian Zhang, Xueli Bai, Tingbo Liang – 23 November 2017 – The development and progression of hepatocellular carcinoma (HCC) are dependent on its local microenvironment. Hypoxia and inflammation are two critical factors that shape the HCC microenvironment; however, the interplay between the two factors and the involvement of cancer cells under such conditions remain poorly understood.

Andrija Matak, Pooja Lahiri, Ethan Ford, Daniela Pabst, Karl Kashofer, Dimitris Stellas, Dimitris Thanos, Kurt Zatloukal – 23 November 2017 – Intratumor heterogeneity is increasingly recognized as a major factor impacting diagnosis and personalized treatment of cancer. We characterized stochastic phenotype switching as a mechanism contributing to intratumor heterogeneity and malignant potential of liver cancer.

Jei‐Ming Peng, Rabindranath Bera, Chih‐Yung Chiou, Ming‐Chin Yu, Tse‐Chin Chen, Chia‐Wei Chen, Tsung‐Rui Wang, Wan‐Ling Chiang, Shin‐Pei Chai, Yongkun Wei, Huamin Wang, Mien‐Chie Hung, Sen‐Yung Hsieh – 23 November 2017 – High invasiveness is a hallmark of human hepatocellular carcinoma (HCC). Large tumors predict invasion and metastasis. Epithelial‐mesenchymal transition (EMT) is crucial for cancer invasion and metastasis. However, the mechanisms whereby large tumors tend to undergo EMT remain unclear.

Andrija Matak, Pooja Lahiri, Ethan Ford, Daniela Pabst, Karl Kashofer, Dimitris Stellas, Dimitris Thanos, Kurt Zatloukal – 23 November 2017 – Intratumor heterogeneity is increasingly recognized as a major factor impacting diagnosis and personalized treatment of cancer. We characterized stochastic phenotype switching as a mechanism contributing to intratumor heterogeneity and malignant potential of liver cancer.

Gin‐Ho Lo, Thomas Reiberger – 23 November 2017

Fredrik Åberg, Jaana Helenius‐Hietala, Pauli Puukka, Martti Färkkilä, Antti Jula – 22 November 2017 – The metabolic syndrome and alcohol risk use are both associated with a high prevalence of hepatic steatosis, but only a minority develop liver failure or liver cancer. Few general population studies have analyzed metabolic predictors of such severe liver complications.

Fredrik Åberg, Jaana Helenius‐Hietala, Pauli Puukka, Martti Färkkilä, Antti Jula – 22 November 2017 – The metabolic syndrome and alcohol risk use are both associated with a high prevalence of hepatic steatosis, but only a minority develop liver failure or liver cancer. Few general population studies have analyzed metabolic predictors of such severe liver complications.

Mauro Borzio, Elena Dionigi, Angelo Rossini, Massimo Marignani, Rodolfo Sacco, Ilario De Sio, Emanuela Bertolini, Giampiero Francica, Anna Giacomin, Giancarlo Parisi, Susanna Vicari, Anna Toldi, Andrea Salmi, Sergio Boccia, Mario Mitra, Fabio Fornari – 22 November 2017 – Several staging systems for hepatocellular carcinoma (HCC) have been developed. The Barcelona Clinic Liver Cancer staging system is considered the best in predicting survival, although limitations have emerged.

Mauro Borzio, Elena Dionigi, Angelo Rossini, Massimo Marignani, Rodolfo Sacco, Ilario De Sio, Emanuela Bertolini, Giampiero Francica, Anna Giacomin, Giancarlo Parisi, Susanna Vicari, Anna Toldi, Andrea Salmi, Sergio Boccia, Mario Mitra, Fabio Fornari – 22 November 2017 – Several staging systems for hepatocellular carcinoma (HCC) have been developed. The Barcelona Clinic Liver Cancer staging system is considered the best in predicting survival, although limitations have emerged.

Edoardo Giovanni Giannini, Laura Bucci, Francesca Garuti, Matteo Brunacci, Barbara Lenzi, Matteo Valente, Eugenio Caturelli, Giuseppe Cabibbo, Fabio Piscaglia, Roberto Virdone, Martina Felder, Francesca Ciccarese, Francesco Giuseppe Foschi, Rodolfo Sacco, Gianluca Svegliati Baroni, Fabio Farinati, Gian Lodovico Rapaccini, Andrea Olivani, Antonio Gasbarrini, Maria Di Marco, Filomena Morisco, Marco Zoli, Alberto Masotto, Franco Borzio, Luisa Benvegnù, Fabio Marra, Antonio Colecchia, Gerardo Nardone, Mauro Bernardi, Franco Trevisani, for the Italian Liver Cancer (ITA.LI.CA) group – 21 November